Skip to main content

White William Richard's Form 4 filing

Akero Therapeutics, Inc. (AKRO) · filed Jul 18, 2024

Accession no.
0000950170-24-084733
Filed
Jul 18, 2024
Trade date
Jul 16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $976.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
White William RichardCIK 0001778739Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 16, 2024Common StockMOption exerciseAcquired+29,803$7.01+$208,919.0376,602Direct
Jul 16, 2024Common StockSSaleDisposed−29,803$28.05F2−$835,974.1546,799Direct
Jul 16, 2024Common StockSSaleDisposed−5,008$28.05F2−$140,474.441,791Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 16, 2024Common StockMOption exerciseDisposed−29,803$0.00$0194,526Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.000 to $28.125, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)